Revolution Medicines, Inc.
Close on Oct 19, 2026
- Market cap
- $38.41B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | – | $-3.06 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | – | $-1.12 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | – | $-0.94 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | $-0.81 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| estimated non-cash stock-based compensation expense | full year 2026 | $270.00M to $290.00M | Raised |
| GAAP operating expenseGAAP | full year 2026 | $2.10B to $2.20B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Revolution Medicines filed with the SEC
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position,
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
FORM OF PARENT STOCKHOLDER VOTING AGREEMENT
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
Results of operations · EX-99 to Form 8-K
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
Results of operations · EX-99 to Form 8-K
On Target to Outsmart Cancer TM January 10, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports First Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Revolution Medicines Reports Fourth Quarter and Year-End 2021
Results of operations · EX-99.1 to Form 8-K
On Target to Outsmart CancerTM
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K